Bemiparin versus unfractionated heparin as bridging therapy in the perioperative management of patients on vitamin K antagonists: the BERTA study.

Abstract:

BACKGROUND AND OBJECTIVE:The management of patients on vitamin K antagonist therapy who require an invasive procedure is problematic. A randomised, controlled, double-blind clinical trial was designed to compare the efficacy and safety of bemiparin, a low molecular weight heparin (LMWH), with unfractionated heparin (UFH) as bridging therapy: the BERTA (BEmiparin Randomised Trial on bridging Anticoagulants) study. METHODS:Two hundred and six patients on long-term oral anticoagulation therapy (OAT) requiring an invasive procedure were randomized to receive bridging therapy with bemiparin + matching placebo or UFH. OAT was resumed on day 1. The study medication was continued for 5-6 days after the procedure. The primary efficacy endpoint was the combined incidence of arterial and venous thromboembolic events. The primary safety endpoint was the incidence of major bleeding within 10 days after the invasive procedure. RESULTS:There were no thromboembolic events in the bemiparin group, but two events (2.2 %) occurred in the UFH group. No major bleeding occurred in either group, but minor bleeding occurred in four patients (4.3 %) and six patients (6.1 %) in the bemiparin and UHF groups, respectively. No deaths and no cases of severe thrombocytopenia occurred during the whole study period. CONCLUSION:Despite its small size, the BERTA study is the first randomised, double-blind clinical trial comparing UFH with a fixed high-risk thromboprophylactic dose of an LMWH as bridging therapy. There were no thromboembolic events and fewer bleeding episodes in the bemiparin group than in the UFH group, hence we suggest that bemiparin is at least as safe as UFH as bridging therapy.

journal_name

Clin Drug Investig

authors

Santamaría A,Ugarriza A,Muñoz C,De Diego I,López-Chulia F,Benet C,Martínez-González J,Gómez N,Pina E,Ortín X,Marco P,Roncalés FJ,Fontcuberta J

doi

10.1007/s40261-013-0141-6

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

921-8

issue

12

eissn

1173-2563

issn

1179-1918

journal_volume

33

pub_type

杂志文章,随机对照试验
  • Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

    abstract::Page 806, column 1, line 3: The text, which previously read. ...

    journal_title:Clinical drug investigation

    pub_type: 已发布勘误

    doi:10.1007/s40261-020-00892-9

    authors: Lyseng-Williamson KA

    更新日期:2020-03-01 00:00:00

  • Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

    abstract:BACKGROUND AND OBJECTIVE:Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0275-9

    authors: McLaughlin MM,Ammar AT,Gerzenshtein L,Scarsi KK

    更新日期:2015-04-01 00:00:00

  • The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea.

    abstract:BACKGROUND AND OBJECTIVE:Polypharmacy, regarded as an indicator of potentially inappropriate medications (PIMs), may lead to a higher risk of serious health consequences in elderly patients with osteoporosis. Thus, this study aimed to analyze the association between polypharmacy and hip fracture in patients with osteop...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0716-3

    authors: Park HY,Kim S,Sohn HS,Kwon JW

    更新日期:2019-01-01 00:00:00

  • Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study.

    abstract:BACKGROUND AND OBJECTIVES:Warfarin-related nephropathy is an unexplained acute kidney injury, and may occur in patients with supratherapeutic INR, in the absence of overt bleeding. Similar findings have been observed in rats treated with dabigatran etexilate. We conducted a prospective study in dabigatran etexilate-tre...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0742-1

    authors: Molteni M,Crippa M,Orenti A,Polo Friz H,Menghini A,Tramacere P,Marano G,Cimminiello C,Boracchi P

    更新日期:2019-04-01 00:00:00

  • Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.

    abstract:OBJECTIVE:This open, prospective, non-interventional, non-randomised, multi-centre postmarketing surveillance study was conducted over a mean period of 13.9 weeks to assess the efficacy, safety and acceptance of acarbose in Chinese patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance (IGT...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.2165/00044011-200727060-00003

    authors: Pan CY,Landen H

    更新日期:2007-01-01 00:00:00

  • Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series.

    abstract:BACKGROUND:Elderly patients are more susceptible to Clostridium difficile infections (CDIs). Despite existing guidelines, there is no specific treatment for CDI in geriatrics. Vancomycin is commonly used in the treatment of CDI. Teicoplanin is an alternative glycopeptide which recently received marketing authorization ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0524-1

    authors: Davido B,Leplay C,Bouchand F,Dinh A,Villart M,Le Quintrec JL,Teillet L,Salomon J,Michelon H

    更新日期:2017-07-01 00:00:00

  • Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients.

    abstract:BACKGROUND:Post-marketing surveillance studies can provide supplemental data on the safety of medications in the general population. OBJECTIVE:This study aimed to evaluate the safety of analgesic regimens including the NSAID lornoxicam in the short-term treatment of postoperative pain in a clinically relevant populati...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11538860-000000000-00000

    authors: Rawal N,Krøner K,Simin-Geertsen M,Hejl C,Likar R

    更新日期:2010-01-01 00:00:00

  • Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases.

    abstract::A pharmacokinetic study was carried out in patients with unresectable colorectal liver metastases who had primarily been included in a phase II trial of intra-arterial cisplatin (DDP) plus intravenous fluorouracil. Ten patients of those accrued for the clinical study underwent the pharmacokinetic investigation upon li...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199612020-00005

    authors: Civalleri D,Esposito M,De Cain F,Balletto N,Mondini G,Gogioso L,Viale M,Vannozzi MO

    更新日期:1996-08-01 00:00:00

  • RETRACTED ARTICLE: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting : Focus on High-Risk Patients.

    abstract::None of the available antiemetics is entirely effective, perhaps because most of them act through the blockade of one receptor. There is a possibility that a combination of antiemetics with different sites of activity would be more effective than one drug alone for prophylaxis against postoperative nausea and vomiting...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,收录出版,评审

    doi:10.2165/00044011-200222090-00001

    authors: Fujii Y

    更新日期:2002-09-01 00:00:00

  • Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

    abstract:BACKGROUND:Rates and impacts of worsening symptoms in patients with psoriasis have not been well characterized. OBJECTIVES:To assess the risk of clinically relevant worsening of psoriasis symptoms in patients treated with adalimumab versus placebo and to determine the health-related quality-of-life (HRQOL) impacts of ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11539360-000000000-00000

    authors: Papp KA,Signorovitch J,Ramakrishnan K,Yu AP,Gupta SR,Bao Y,Mulani PM

    更新日期:2011-01-01 00:00:00

  • Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.

    abstract:BACKGROUND AND OBJECTIVES:A new oral antidiabetic drug class, sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), has been covered by national health insurance in Taiwan since May 2016. This study estimated the impacts of insurance coverage for SGLT-2 inhibitors on the replacement effects of antidiabetic dr...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0689-2

    authors: Chen HY,Chiu PY,Chang CJ,Tsai LL,Huang YL,Hsu JC

    更新日期:2018-12-01 00:00:00

  • Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.

    abstract:BACKGROUND AND OBJECTIVES:Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the treatment of attention-deficit/hyperactivity disorder (ADHD). Uniquely, relative to current ADHD medications, dasotraline has a slow absorption and long elimination...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0358-7

    authors: Hopkins SC,Sunkaraneni S,Skende E,Hing J,Passarell JA,Loebel A,Koblan KS

    更新日期:2016-02-01 00:00:00

  • Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.

    abstract:BACKGROUND AND OBJECTIVES:Vedolizumab, a humanized monoclonal antibody against the α4β7 integrin, is indicated for treatment of moderately to severely active ulcerative colitis or Crohn's disease. In this placebo-controlled, double-blind, randomized, single ascending-dose study, the pharmacokinetics, pharmacodynamics, ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-016-0437-4

    authors: Rosario M,Wyant T,Leach T,Sankoh S,Scholz C,Parikh A,Fox I,Feagan BG

    更新日期:2016-11-01 00:00:00

  • CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

    abstract::Cytochrome P450 (CYP) 3A4 has been considered to be the most important enzyme system for metabolism of lopinavir/ritonavir (LPV/r), a widely used HIV protease inhibitor (PI) recommended during pregnancy. Herein we present a clinical case of a pregnant HIV-infected woman who was taking standard doses of LPV/r, 400/100 ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0245-7

    authors: López Aspiroz E,Cabrera Figueroa SE,Iglesias Gómez A,Valverde Merino MP,Domínguez-Gil Hurlé A

    更新日期:2015-01-01 00:00:00

  • Effectiveness of an Intervention to Improve Management of COPD using the AUDIT Methodology: Results of the Neumo-Advance Study.

    abstract:BACKGROUND AND OBJECTIVE:The implementation of chronic obstructive pulmonary disease (COPD) guidelines in the real-world setting remains low. Pulmonologists should participate in the new paradigms of chronicity of COPD, by providing their knowledge, expertise, innovation and research. The objective of this study was to...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00787-4

    authors: de Miguel-Díez J,Jiménez-García R,López de Andrés A,Zaragoza Arnáez F

    更新日期:2019-07-01 00:00:00

  • Diclofenac epolamine (Flector) patch: evidence for topical activity.

    abstract::This review focuses on previously unpublished clinical and pharmacokinetic data with the diclofenac epolamine (diclofenac hydroxyethylpyrrolidine) patch supporting the hypothesis of a topical effect of this formulation. Previous studies have shown that 1 or 2 weeks of treatment with diclofenac epolamine provides pain ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/0044011-200929010-00001

    authors: Petersen B,Rovati S

    更新日期:2009-01-01 00:00:00

  • Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.

    abstract:BACKGROUND:Among the many consequences of loss of CFTR protein function, a significant reduction of the secretion of bicarbonate (HCO3-) in cystic fibrosis (CF) is a major pathogenic feature. Loss of HCO3- leads to abnormally low pH and impaired mucus clearance in airways and other exocrine organs, which suggests that ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00861-x

    authors: Gomez CCS,Parazzi PLF,Clinckspoor KJ,Mauch RM,Pessine FBT,Levy CE,Peixoto AO,Ribeiro MÂGO,Ribeiro AF,Conrad D,Quinton PM,Marson FAL,Ribeiro JD

    更新日期:2020-02-01 00:00:00

  • Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.

    abstract:OBJECTIVE:To compare the real-life treatment of acute exacerbations of chronic bronchitis (AECBs) using moxifloxacin tablets or one of the oral macrolides azithromycin, clarithromycin or roxithromycin in terms of symptom relief, time until improvement and cure, overall efficacy and tolerability. METHODS:This prospecti...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.2165/00044011-200626120-00007

    authors: Schaberg T,Möller M,File T,Stauch K,Landen H

    更新日期:2006-01-01 00:00:00

  • US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.

    abstract::Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0492-5

    authors: Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

    更新日期:2017-04-01 00:00:00

  • Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.

    abstract:BACKGROUND AND OBJECTIVES:The time-course when changes in glycemic control and body weight were first manifest in patients with type 2 diabetes mellitus (T2DM) treated with a combination of insulin degludec and liraglutide (IDegLira) was assessed, comparing IDegLira to its individual components. METHODS:Data from week...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-016-0376-0

    authors: Vilsbøll T,Vora J,Jarlov H,Kvist K,Blonde L

    更新日期:2016-04-01 00:00:00

  • Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain.

    abstract::Opioids are the most powerful analgesic drugs currently available and consequently form an essential part of the treatment options for malignant and non-malignant chronic pain. However, the benefits of these medications can be offset by gastrointestinal adverse events such as nausea, vomiting and constipation, as well...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/BF03256935

    authors: Annemans L

    更新日期:2011-01-01 00:00:00

  • Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.

    abstract:BACKGROUND AND OBJECTIVES:Oxycodone tamper resistant (OTR) is a new extended-release abuse-deterrent formulation providing improvements in the tamper resistant characteristics. This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-019-00870-w

    authors: Luo Z,Miao J,Shu S,Wang Y,Zhu X,Hu C,Shen Y

    更新日期:2020-02-01 00:00:00

  • Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.

    abstract::Doravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) infection. The recommended dose is 100 mg once daily. This review summarizes the pharmacokinetics of doravirine, the influence of intrinsic factors, and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-020-00934-2

    authors: Khalilieh S,Yee KL,Sanchez R,Stoch SA,Wenning L,Iwamoto M

    更新日期:2020-10-01 00:00:00

  • Role of lormetazepam in the treatment of insomnia in the elderly.

    abstract:BACKGROUND AND OBJECTIVE:Sleep architecture changes with age, both in terms of efficiency and total duration of sleep. Hypnotic benzodiazepines promote rapid onset of sleep, uninterrupted sleep and longer duration of sleep in the absence of carryover sedation the following morning; therefore, these may be appropriate f...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200727050-00003

    authors: De Vanna M,Rubiera M,Onor ML,Aguglia E

    更新日期:2007-01-01 00:00:00

  • Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.

    abstract:BACKGROUND AND OBJECTIVE:Gemigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. This study evaluated possible pharmacodynamic and pharmacokinetic interactions between gemigliptin and metformin and investigated their tolerability. METHODS:A randomized, open-la...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-014-0184-3

    authors: Shin D,Cho YM,Lee S,Lim KS,Kim JA,Ahn JY,Cho JY,Lee H,Jang IJ,Yu KS

    更新日期:2014-06-01 00:00:00

  • Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.

    abstract:BACKGROUND:Dutasteride is a dual inhibitor of type I and type II 5α-reductases and provides nearly complete suppression of dihydrotestosterone, which plays a key role in the aetiology and development of benign prostatic hyperplasia (BPH). Most knowledge about the efficacy and safety of dutasteride in BPH derives from t...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11593750-000000000-00000

    authors: Na Y,Ye Z,Zhang S,Chinese Dutasteride Phase III Trial (ARIA108898) Study Group.

    更新日期:2012-01-01 00:00:00

  • Selective serotonin reuptake inhibitor use in primary care: a 5-year naturalistic study.

    abstract:OBJECTIVE:To investigate prescribing trends of selective serotonin reuptake inhibitors (SSRIs) during the course of the Defeat Depression Campaign (1992 to 1996). METHODS:This study utilised cross-sectional data on the prescribing of SSRIs for the treatment of depression from a large primary care database for the 5 co...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199816060-00005

    authors: Donoghue J

    更新日期:1998-01-01 00:00:00

  • Amlexanox for the treatment of recurrent aphthous ulcers.

    abstract::Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. The minor manifestation of the condition is the most common and is characterised by small, shallow, round or oval lesions that are surrounded by a raised erythematous h...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525090-00001

    authors: Bell J

    更新日期:2005-01-01 00:00:00

  • West Syndrome: A Review and Guide for Paediatricians.

    abstract::West syndrome (WS), also known as infantile spasms, occurs in infancy with a peak between 4 and 7 months. Spasms, neurodevelopmental regression and hypsarrhythmia on electroencephalogram (EEG) basically define WS. The International League Against Epilepsy commission classifies the aetiologies of WS into genetic, struc...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-017-0595-z

    authors: D'Alonzo R,Rigante D,Mencaroni E,Esposito S

    更新日期:2018-02-01 00:00:00

  • Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

    abstract::The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0260-8

    authors: Kishimoto M,Noda M

    更新日期:2015-02-01 00:00:00